

RESEARCH

Open Access

Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain

Samira Saadoun¹, Patrick Waters², Gregory P Owens³, Jeffrey L Bennett^{3,4}, Angela Vincent²
and Marios C Papadopoulos^{1*}

Abstract

Introduction: Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) are present in some neuromyelitis optica patients who lack antibodies against aquaporin-4 (AQP4-IgG). The effects of neuromyelitis optica MOG-IgG in the central nervous system have not been investigated *in vivo*. We microinjected MOG-IgG, obtained from patients with neuromyelitis optica, into mouse brains and compared the results with AQP4-IgG.

Results: MOG-IgG caused myelin changes and altered the expression of axonal proteins that are essential for action potential firing, but did not produce inflammation, axonal loss, neuronal or astrocyte death. These changes were independent of complement and recovered within two weeks. By contrast, AQP4-IgG produced complement-mediated myelin loss, neuronal and astrocyte death with limited recovery at two weeks.

Conclusions: These differences mirror the better outcomes for MOG-IgG compared with AQP4-IgG patients and raise the possibility that MOG-IgG contributes to pathology in some neuromyelitis optica patients.

Keywords: Antibody, Demyelination, Myelin oligodendrocyte glycoprotein, Neuromyelitis optica

Introduction

Most neuromyelitis optica (NMO) patients have IgG against aquaporin-4 (AQP4), here termed AQP4-IgG [1,2]. AQP4 is a water channel protein found in astrocytes throughout the central nervous system (CNS), especially in perivascular astrocyte foot processes [3]. In cultured cells, AQP4-IgG binds extracellular conformational domains of AQP4 and activates complement, causing cell lysis [4]. In mice, intracerebral injection of AQP4-IgG activates co-injected human complement (C_{hu}) and damages the astrocytes [5,6]. Inflammatory cells then enter the lesion causing further tissue injury including demyelination and axonal damage. In AQP4-IgG NMO patients, recovery after an attack is usually limited [7-9].

A few NMO patients without AQP4-IgG have IgG against myelin oligodendrocyte glycoprotein (MOG-IgG), which recognize extracellular conformational domains of MOG [10-13]. MOG is expressed on the outer surface of CNS myelin sheaths and comprises about 0.05% of total

myelin protein [14]. There is mounting evidence that MOG-IgG NMO has more favorable clinical outcome than AQP4-IgG NMO, with resolution of imaging abnormalities [10,11,15,16]. It is currently unclear whether MOG-IgG plays any role in NMO by causing lesions in the CNS *in vivo*. Here we compared the effects of MOG-IgG with those of AQP4-IgG in the intracerebral injection mouse model. We used total IgG from a normal subject (IgG_{CON}) and from NMO patients with AQP4-IgG (IgG_{AQP4}) or MOG-IgG (IgG_{MOG}).

Materials and methods

IgG and complement

NMO patients with MOG-IgG or AQP4-IgG were identified using live cell-based assays. Briefly, AQP4-IgG and MOG-IgG positivity was determined by visualization of binding to human embryonic kidney cells, transfected with the extracellular and trans-membrane domains of MOG or with full-length M23-AQP4. Details of the assays are given elsewhere [5,10,11,15]. IgG was purified using Protein G from sera or plasmas of five patients with AQP4-IgG NMO, five MOG-IgG NMO or one healthy volunteer. The effect of injecting IgG and C_{hu} from healthy volunteers into mouse brain was extensively investigated in our earlier

* Correspondence: mpapadop@sgul.ac.uk

¹Academic Neurosurgery Unit, St. George's, University of London, London, UK
Full list of author information is available at the end of the article

studies [5,17,18]. The purified, dialysed and pooled total IgG preparations (6 – 38 mg/ml) are termed IgG_{AQP4}, IgG_{MOG} and IgG_{CON}. Clinical details of the 5 AQP4-IgG + [5] and 5 MOG-IgG + [11,15] patients are given elsewhere. To deplete MOG-IgG, the IgG_{MOG} was adsorbed by incubation with MOG-HEK cells until MOG-IgG became undetectable (IgG_{MOG(AdsMOG-HEK)}). IgG_{MOG} adsorbed against untransfected HEK cells (IgG_{MOG(AdsHEK)}) was used as control. A chimeric mouse-human recombinant monoclonal anti-mouse MOG antibody, MOG-IgG_{2B7}, was produced as described [19]. Human recombinant monoclonal anti-AQP4 IgG₁, termed AQP4-IgG₅₃, was also generated [20]. A measles virus-specific antibody termed CON-IgG_{2B4} was used as isotype control [20]. The source of C_{hu} was fresh serum from healthy volunteers [5].

Mice

Experiments were performed at St. George's, University of London using CD1 mice 8 – 12 30 – 35 g, 8 – 12w old. Protocols were approved by the British Home Office (Project Licence, PPL 70/7081). After administering 2,2,2-tribromoethanol i.p., mice were mounted onto a stereotaxic frame (Benchmark, Neurolab, St Louis, MO, USA). Four burrholes were made on the right side using a high speed drill (0.7 mm burr, Foredom, Bethel, CT, USA) at the following coordinates in millimetres from the bregma (lateral, anterior): (1, 0), (1, -1), (1, -2), (2, -1). Mice were allocated to the different experimental groups by a person unaware of the aim of the study. A 30 g needle attached to 50 ml gas-tight glass syringe (Hamilton, Reno, NV, USA) was inserted 3 mm deep to micro-infuse (1 µL/min) into the right hemisphere 16.8 µL IgG_{MOG}, IgG_{AQP4} or IgG_{CON} or 16.8 µL (20 µg) MOG-IgG_{2B7} or AQP4-IgG₅₃ + 11.2 µL C_{hu} (or normal saline) as described [5]. Rectal temperature was kept 37 – 38°C with a heating lamp. After regaining the righting reflex, mice were returned to their cages, kept in 12 hour light/dark cycle and given water and normal chow *ad libitum*. Mice (5 per group) were killed at 24 hours, seven days or two weeks. Investigators were unaware of which antibody was injected.

Mouse brain histology and immunohistology

Mice were anaesthetized and perfused-fixed by injecting 4% formaldehyde through the left cardiac ventricle. Brains were removed, post-fixed in 4% formaldehyde overnight and processed into paraffin. Coronal tissue sections (7 µm thick) through the injection tract were stained with H + E, Luxol Fast Blue (LFB) [5] or immunostained.

For diaminobenzidine immunostaining, the sections were unmasked in citrate, incubated with primary antibody (one hour, 25°C), biotinylated secondary antibody (1:500, one hour, 25°C) and visualized using the Vectastain

HRP kit (Vector Labs, Peterborough, UK). We counterstained nuclei with haematoxylin. Primary antibodies were rabbit anti-AQP4 (1:100), rabbit anti-glial fibrillary acidic protein (GFAP, 1:200), mouse anti-NeuN (1:200), (Millipore, Livingstone, UK), mouse anti-myelin basic protein (MBP, 1:400, Leica, Newcastle, UK), mouse anti-neurofilament-70 (1:600, DAKO, Ely, UK), rabbit anti-C5b-9 (1:100, Abcam, Cambridge, UK) and rat anti-CD45 (1:200, BD Bioscience, Oxford, UK). Samples were then incubated with the appropriate species biotinylated secondary antibody (1:500, Vector Laboratories). Immunostaining was visualized brown using the Vectastain horseradish peroxidase kit (Vector Laboratories) followed by diaminobenzidine/H₂O₂. Nuclei were counterstained blue with haematoxylin.

For immunofluorescence staining, we used rabbit anti-Ankyrin G (AnkG, InsightBio, Wembley, UK) or rabbit anti-Contactin associated protein (Caspr) from Abcam (1:200, 12 hours, 25°C) followed by Alexafluor-linked anti-rabbit antibody (1:200, one hour, 25°C, Invitrogen, Paisley, UK).

To determine MOG-IgG binding to mouse brain sections, brains were removed, immersed in 30% sucrose overnight, embedded in OCT and cut into 7 µm sections. These were fixed in acetone and exposed to IgG_{MOG(AdsHEK)}, IgG_{MOG(AdsMOG-HEK)}, IgG_{CON} (1:100) or MOG-IgG_{2B7} (1 mg/mL) ± rabbit anti-MOG (1:100, InsightBio) for one hour at 25°C followed by Alexafluor-linked anti-human ± anti-rabbit IgG (1:200, one hour, 25°C, Invitrogen) and DAPI.

Photomicrographs were taken using an Olympus BX-51 microscope.

Data analysis

Coded photomicrographs were analysed with ImageJ (v1.45S, NIH). Neurofilament immunoreactivity in the injected hemisphere was quantified as mean staining intensity minus background. AnkG and Caspr expression was the number of fluorescent spots/mm² in four photomicrographs, 90 µm × 67 µm, taken from the injected hemisphere 0.5 mm from the needle tract. After subtracting background, formatting images to 8-bit, adjusting threshold, the 'analyse particles' function of Image J was used. Spots < 0.01 µm² were excluded as noise.

Statistics

Data are mean ± standard error. We used Student t-test or ANOVA with Student-Newman-Keuls *post-hoc* analysis. Significance is $P < 0.05^*$, 0.01^{**} , 0.001^{***} .

Results

Lesions induced by IgG_{MOG} compared to IgG_{AQP4}

IgG_{MOG} + C_{hu} caused brain edema at 24 hours, but by seven days and two weeks the brain appeared normal

(Figure 1A). Although IgG_{AQP4} + C_{hu} also caused edema at 24 hours, at seven days there was marked leukocyte infiltration and by two weeks reactive gliosis (Figure 1A). IgG_{MOG} + C_{hu} caused loss of Luxol Fast Blue (LFB) staining at 24 hours, but this had reversed by two weeks, while the IgG_{AQP4} + C_{hu} - injected tissue showed increased loss of LFB staining at seven days and only partially recovered at two weeks (Figure 1B). The recruitment of inflammatory cells also differed markedly between the two preparations. IgG_{MOG} + C_{hu} did not produce inflammation while IgG_{AQP4} + C_{hu} caused inflammation at 24 hours (perivascular neutrophils) and seven days (mostly macrophages) (Figure 1C).

We immunostained for two astrocyte markers, AQP4 and GFAP. Loss of AQP4 and GFAP was seen in

IgG_{AQP4} + C_{hu} - injected brains (at 24 hours and seven days) but IgG_{MOG} + C_{hu} did not reduce AQP4 and GFAP (Figure 2). At two weeks there was marked gliosis (increased AQP4 and GFAP) in brains injected with IgG_{AQP4} + C_{hu}, compared to little gliosis in brains that received IgG_{MOG} + C_{hu} (Figure 2).

MOG-IgG binds mouse MOG and causes loss of LFB staining

To confirm that IgG_{MOG} binds mouse myelin, it was applied to brain sections. IgG_{MOG} bound the corpus callosum; binding co-localized with a commercial anti-MOG antibody (Figure 3A). IgG_{MOG} adsorbed by incubation with MOG-expressing human embryonic kidney (MOG-HEK) cells until MOG-IgG became undetectable





Figure 1 Brain lesions caused by MOG-IgG and AQP4-IgG. Mice received IgG_{CON} + C_{hu} (purple), IgG_{MOG} + C_{hu} (green) or IgG_{AQP4} + C_{hu} (blue), were killed at 24 hours (d1), seven days (d7) or two weeks (d14) and coronal brain sections were cut through the injection site. **A.** H + E staining. Ed, edema; L, lumen; leuko, leukocytes; RG, reactive gliia; wm, white matter. **B.** (Top) LFB staining. Red line, loss of LFB staining. (Bottom) % Loss of LFB stain (area without LFB/ipsilateral hemispheric area) vs. days since injection. **C.** (Top) CD45 immunostain. Each boxed area in d7 top is shown magnified below. Arrows, CD45+ cells; L, vessel lumen; mφ, macrophages. (Bottom) % CD45+ area (CD45+ area/ipsilateral hemispheric area) vs. days since injection. Mean ± SEM, 5 mice per group. P < 0.01**, 0.001*** (compared with each of the other two groups). Bar 50 μm (A), 1 mm (B, C d7 top), 20 μm (C d7 bottom).



(IgG_{MOG(AdsMOG-HEK)}) did not bind the corpus callosum, unlike IgG_{MOG} adsorbed against untransfected HEK cells (IgG_{MOG(AdsHEK)}) (Figure 3B). To confirm that the MOG-IgG was responsible for the loss of LFB staining, the two adsorbed preparations were injected with C_{hu} and mice were killed at seven days. Loss of LFB staining in the injected hemisphere was only found when IgG_{MOG(AdsHEK)} + C_{hu} was used (Figure 3C).

MOG-IgG_{2B7} causes loss of LFB staining largely independent of immune cells or complement activation

In case the amount of MOG-IgG in the patient preparations was insufficient to cause inflammatory cell infiltration, a large amount (20 μg) of the humanized anti-mouse MOG-IgG_{2B7} was co-injected with C_{hu}. At seven days, MOG-IgG_{2B7} + C_{hu} caused loss of LFB staining, but without inflammatory cell infiltration (Figure 4A). At 24 hours after injecting MOG-IgG_{2B7} + C_{hu} there was faint C5b-9 immunoreactivity in white matter tracts suggesting slight complement activation, whereas injection of a monoclonal recombinant anti-AQP4 (AQP4-IgG₅₃) + C_{hu} caused strong perivascular C5b-9 immunoreactivity (Figure 4B). Moreover, intracerebral injection of MOG-IgG_{2B7} without C_{hu} produced loss of LFB staining at 24 hours similar to MOG-IgG_{2B7} + C_{hu} (Figure 4C).

MOG-IgG causes reversible damage to myelinated axons

At two weeks there was marked neuronal loss in IgG_{AQP4} + C_{hu} lesions compared to little neuronal loss in brains injected with IgG_{MOG} + C_{hu} (Figure 5A). We investigated the effect of IgG_{MOG} + C_{hu} on myelin and axonal proteins including myelin basic protein (MBP), neurofilament, ankyrin G (AnkG) and contactin associated protein (Caspr) (Figure 5B). MBP adheres adjacent cytoplasmic faces of myelin together, neurofilament provides structural support for axons, AnkG clusters voltage-gated Na⁺ channels at nodes of Ranvier [21] and Caspr attaches paranodal myelin loops to the axons [22]. At 24 hours after IgG_{MOG} + C_{hu} injection, MBP expression appeared abnormal (Figure 5C) and there was significant reduction in AnkG (Figure 5D) and Caspr (Figure 5E) immunoreactivities. At two weeks, the MOG-IgG + C_{hu} - induced changes in MBP, AnkG and Caspr had recovered and neurofilament expression was normal (Figure 5F), indicating intact axons.

Discussion

Although there is growing interest in the potential pathogenicity of MOG antibodies in NMO, the effects of NMO MOG-IgG have not been explored *in vivo*. Our results indicate that MOG-IgG directly damages myelin. The detrimental effects of MOG-IgG markedly differ from those of AQP4-IgG and are reversible (see Table 1).





Figure 3 MOG-IgG binds mouse MOG and causes loss of LFB staining. **A.** Mouse corpus callosum (CC) fluorescently immunostained with IgG_{MOG} (green) and anti-MOG (red). DAPI nuclear stain. **B.** CC immunostained fluorescent red with IgG_{MOG}, IgG_{MOG(AdsMOG-HEK)}, MOG-IgG_{2B7} and IgG_{CON}. DAPI nuclear stain. Insets – immunopositive (DAB) gray matter neurons. **C.** Mouse brain injected with IgG_{MOG(AdsHEK)} + C_{hu} or IgG_{MOG(AdsMOG-HEK)} + C_{hu}. (Top) LFB stained sections at 24 hours. Red line, no LFB staining. (Bottom). Data summary. 5 mice per group. Mean ± SEM. P < 0.05*. Bar 10 μm (A insets), 50 μm (A, B), 1 mm (C).

AQP4-IgG lesions are characterized by astrocyte damage followed by leukocyte infiltration that entirely depend on complement activation [5]. We showed that recovery of myelin loss in AQP4-IgG lesions is limited, with gliosis and neuronal death. This finding may explain why clinical recovery after AQP4-IgG NMO attacks is often limited [7-9]. By contrast, MOG-IgG, as examined here, damages myelin and axons temporarily, with little complement activation, and no leukocyte infiltration. The myelin and axonal recovery and lack of neuronal death mirror the reported good outcomes of MOG-IgG NMO patients [10,11,15,16].

One study suggested that IgG_{MOG} obtained from children with demyelination does not bind mouse MOG [23], but another study showed that human MOG-IgG binds mouse MOG [24]. Our IgG_{MOG} samples obtained from adult NMO patients, and the anti-mouse MOG-specific monoclonal antibody, both recognized mouse MOG in frozen brain sections, and produced comparable LFB loss without inflammation. This discrepancy may be due to differences in MOG-IgG levels and specificity or differences in MOG glycosylation state, which plays a key role in MOG-IgG binding [24], between children and adults.

The effects of MOG-IgG on cultured oligodendrocytes have already been studied. MOG-IgG binds extracellular epitopes on MOG [23] and can cause crosslinking [25] and internalization [12] of MOG molecules and reversible retraction of oligodendrocyte processes [25]. At high concentration, MOG-IgG causes complement-mediated lysis of MOG-expressing cells [12]. Passive transfer of MOG-IgG antibodies exacerbates CNS damage in experimental autoimmune encephalomyelitis rodent models in which cellular immunity is the predominant pathogenic mechanism [26,27]. Using the intracerebral injection mouse model, we have shown unequivocally that NMO MOG-IgG directly damages myelin *in vivo* independent of pre-existing cellular immunity and complement.

MOG-IgG changed MBP architecture and reduced expression of axonal proteins. Caspr and AnkG are required for the integrity of the nodes of Ranvier and normal action potential firing [21,22]. Mice that lack MBP have a



characteristic motor dysfunction including tremor and seizures [28], mice that lack Caspr have severe motor paresis [22] whereas mice lacking cerebellar ankG develop progressive ataxia [21]. Therefore, the altered MBP expression and reduced Caspr and AnkG expression produced by MOG-IgG are predicted to produce a neurological deficit if the NMO lesion is in an eloquent region of the CNS. Unlike AQP4-IgG, MOG-IgG did not produce axonal disintegration or neuronal death. Given the 96% homology between mouse and human MOG [14], our findings raise the possibility that MOG-IgG may also cause similar reversible lesions in the human CNS.

MOG-IgG has been reported in other non-NMO diseases including multiple sclerosis, acute disseminated encephalomyelitis and even some normal subjects [29]. Does MOG-IgG from these non-NMO subjects also cause the same reversible CNS changes, as described here for NMO MOG-IgG? This question is difficult to answer at present because of the variety of assays used to detect MOG-IgG. For example, the assay used here, which employs C-terminal truncated rather than full-length MOG, did not detect MOG-IgG in adult multiple sclerosis patients and normal individuals [11], which suggests that different assays detect different subpopulations of MOG-IgG. It is important to first standardize the assays before determining which subpopulations of MOG-IgG can cause CNS damage and in which diseases.

The mechanism of MOG-IgG-induced myelin damage *in vivo* is unknown. Our data show that MOG-IgG mediated myelin damage is a direct effect of MOG-IgG and that complement activation is not necessary. MOG-IgG binding may cause MOG conformational changes or internalization that disrupts the myelin structure and secondarily alters axonal protein expression. To explain the lack of complement involvement, we hypothesize that, after MOG-IgG binding, MOG might not aggregate (because of its low abundance) or MOG might become internalized (thus prohibiting C1q activation). The full recovery within two weeks of the MOG-IgG-induced LFB, MBP, ankG and Caspr changes suggests that MOG-IgG does not kill the oligodendrocytes, but causes a reversible damage.

Our findings raise the possibility that MOG-IgG contributes to pathology in some NMO patients. If MOG-IgG is pathogenic, antibody depletion (plasmapheresis) or suppression with steroids should be effective, as indeed appears to be the case [10,11,15,16]. Conversely, some of the newly proposed therapies for AQP4-IgG NMO, such as sivelestat for inhibiting neutrophils [17], or eculizumab for inhibiting complement [30], are less likely to be needed in MOG-IgG NMO. Examining lesions from MOG-IgG NMO patients may help elucidate the pathogenicity of MOG-IgG in the human CNS.




Figure 5 Effect of MOG-IgG on neurons. **A** (Left) NeuN immunoreactivity at 2w. Area lacking neurons outlined red. (Right) % NeuN loss (NeuN immunonegative area/ipsilateral hemispheric area). **B** Node of Ranvier: ankG, ankyrin G; Caspr, contactin associated protein; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; Na_v, voltage-gated Na⁺ channel; Nfil, neurofilament. **C**. MBP immunoreactivity. (Top) Normal and abnormal white matter tracts. (Bottom) % abnormal tracts in injected hemisphere. **D**. Caspr immunoreactivity within white matter tracts. (Top) Hemispheres injected with IgG_{CON} + C_{hu} and IgG_{MOG} + C_{hu}. (Bottom) Data summary. **E**. AnkG immunoreactivity within white matter tracts. (Top) Hemispheres injected with IgG_{CON} + C_{hu} and IgG_{MOG} + C_{hu}. (Bottom) Data summary. **F**. Nfil immunoreactivity. (Top) Hemispheres injected with IgG_{CON} + C_{hu} and IgG_{MOG} + C_{hu}. Arrowheads: white matter tracts. (Bottom) Data summary (a.u. arbitrary units). 5 mice per group. P <0.05*, <0.01**. Bar 0.5 mm (A), 20 μm (C), 10 μm (D, E), 50 μm (F).

Conclusions

MOG-IgG obtained from neuromyelitis optica patients causes myelin changes and alters the expression of axonal proteins when injected in mouse brain. These effects are not associated with inflammatory cell infiltration, are largely independent of complement and recover within two weeks. AQP4-IgG obtained from neuromyelitis optica patients causes complement-mediated myelin loss, inflammatory

cell infiltration, neuronal and astrocyte death with limited recovery at two weeks. These findings raise the possibility that MOG-IgG contributes to pathology in some neuromyelitis optica patients.

Availability of supporting data

No supporting data.

Table 1 Comparison of MOG-IgG with AQP4-IgG lesions in mouse brain

Characteristic	MOG-IgG	AQP4-IgG
Target cell	Oligodendrocyte (myelin)	Astrocyte (foot process)
Lesion onset	Within hours of exposure to MOG-IgG	Within hours of exposure to AQP4-IgG
Effect on astrocytes	No major effect (normal AQP4 and GFAP)	Astrocyte death (loss of AQP4 and GFAP)
Effect on neurons	No major effect	Neuronal death (loss of NeuN, FJ-C staining [5])
Effect on oligodendrocytes	Change in myelin (loss of LFB)	Loss of myelin (loss of LFB)
Effect on axons	Myelin (transient change in MBP) Intact axons (normal nfil) Node of Ranvier (transient change in casp and ankG)	Permanent loss of myelin Axonal degeneration (β-APP expression [5])
Inflammatory cell infiltration	No	Yes
Complement activation	Slight (in white matter tracts) Not required for lesion to develop	Marked (perivascular) Essential for lesion to develop
Recovery	Yes, within 2 weeks	No, pan-necrosis followed by glial scarring

β-APP, beta amyloid precursor protein; FJ-C, fluorojade C; GFAP, glial fibrillary acidic protein; LFB, Luxol fast blue; MBP, myelin basic protein; NeuN, neuronal nuclear marker; nfil, neurofilament.

Abbreviations

AnkG: Ankyrin G; AQP4: Aquaporin-4; AQP4-IgG: Aquaporin-4 IgG found in most neuromyelitis optica patients; C5b-9: Complement membrane attack complex; Caspr: Contactin associated protein; C_{1q}: Human complement; CNS: Central nervous system; CON-IgG_{2B4}: Monoclonal (2B4) control IgG; GFAP: Glial fibrillary acidic protein; H + E: Hematoxylin and eosin; IgG_{AQP4}: IgG fraction of serum from neuromyelitis optica patients containing AQP4-IgG; IgG_{CON}: IgG fraction of serum from normal subjects; IgG_{MOG}: IgG fraction of serum from neuromyelitis optica patients containing MOG-IgG; IgG_{MOG(AdsHEK)}: IgG_{MOG} adsorbed against untransfected HEK cells; IgG_{MOG(AdsMOG-HEK)}: IgG_{MOG} adsorbed against MOG-HEK to deplete MOG-IgG; LFB: Luxol fast blue; MBP: Myelin basic protein; MOG: Myelin oligodendrocyte glycoprotein; MOG-IgG_{2B7}: Chimeric anti-mouse MOG recombinant IgG in which the constant mouse regions of the heavy and light chains were substituted with the human IgG₁ constant regions, C_{H1} and C_κ; NeuN: Neuronal nuclei; Nfil: Neurofilament; NMO: Neuromyelitis optica.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SS designed and carried out the animal experiments, analyzed the data, produced the figures, contributed key ideas and helped draft the manuscript. PW prepared the IgG patient samples and contributed key ideas. GPO produced the recombinant MOG-IgG antibody. JLB produced the recombinant AQP4-IgG antibody and contributed key ideas. AV contributed key ideas and helped to draft the manuscript. MCP participated in the design and coordination of the study and wrote manuscript. All authors read and approved the final manuscript.

Acknowledgements

Funded by a research grant from the Guthy Jackson Charitable Foundation to MCP. PW and AV are supported by the Oxford NIHR Biomedical Research Centre and the NHS Specialised Services for NMO. JLB is supported by the Guthy-Jackson Charitable Foundation and the NIH (EY022936). GPO is supported by the NIH (NS072141).

Author details

¹Academic Neurosurgery Unit, St. George's, University of London, London, UK. ²Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK. ³Department of Neurology, University of Colorado Denver, Aurora, Colorado, USA. ⁴Department of Ophthalmology, University of Colorado Denver, Aurora, Colorado, USA.

Received: 9 March 2014 Accepted: 9 March 2014

Published: 31 March 2014

References

- Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, Palace J, Mandrekar JN, Vincent A, Bar-Or A, Pittock SJ: **Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.** *Neurology* 2012, **78**(9):665–671. discussion 669. doi:10.1212/WNL.0b013e318248dec1.
- Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR: **IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.** *J Exp Med* 2005, **202**(4):473–477. doi:10.1084/jem.20050304.
- Papadopoulos MC, Verkman AS: **Aquaporin water channels in the nervous system.** *Nat Rev Neurosci* 2013, **14**(4):265–277. doi:10.1038/nrn3468.
- Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, Lennon VA: **Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica.** *Neurology* 2007, **69**(24):2221–2231. doi:10.1212/01.WNL.0000289761.64862.ce.
- Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC: **Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.** *Brain* 2010, **133**(Pt 2):349–361.
- Papadopoulos MC, Verkman AS: **Aquaporin 4 and neuromyelitis optica.** *Lancet Neurol* 2012, **11**(6):535–544. doi:10.1016/S1474-4422(12)70133-3.
- Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG: **NMO-IgG predicts the outcome of recurrent optic neuritis.** *Neurology* 2008, **70**(23):2197–2200.
- Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Bretschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, et al: **Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients.** *J Neuroinflammation* 2012, **9**(1):14. doi:10.1186/1742-2094-9-14.
- Akman-Demir G, Tuzun E, Waters P, Icoz S, Kurtuncu M, Jarius S, Yapici Z, Mutlu M, Yesilot N, Vincent A, Eraksoy M: **Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients.** *J Neurol* 2011, **258**(3):464–470. doi:10.1007/s00415-010-5780-4.
- Kitley J, Leite MI, Kuker W, Quaghebeur G, George J, Waters P, Woodhall M, Vincent A, Palace J: **Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies.** *JAMA Neurol* 2013. Epub ahead of print. doi:10.1001/jamaneurol.2013.3890.
- Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, Palace J, Vincent A: **Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.** *Neurology* 2012, **79**(12):1273–1277. doi:10.1212/WNL.0b013e31826aac4e.
- Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A, Jarius S, Di Pauli F, Kuenz B, Ehling R, Hegen H, Deisenhammer F, Aboul-Enein F, Storch MK, Koson P, Drulovic J, Kristoferitsch W, Berger T, Reindl M: **Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.** *J Neuroinflammation* 2011, **8**:184. doi:10.1186/1742-2094-8-184.
- Rostasy K, Mader S, Hennes EM, Schanda K, Gredler V, Guenther A, Blaschek A, Korenke C, Pritsch M, Pohl D, Maier O, Kuchukhidze G, Brunner-Krainz M, Berger T, Reindl M: **Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.** *Mult Scler* 2013, **19**(8):1052–1059. doi:10.1177/1352458512470310.
- Vourc'h P, Andres C: **Oligodendrocyte myelin glycoprotein (OMgp): evolution, structure and function.** *Brain Res Brain Res Rev* 2004, **45**(2):115–124. doi:10.1016/j.brainresrev.2004.01.003.
- Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, Kuker W, Chandratte S, Vincent A, Palace J: **Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.** *JAMA Neurol* 2014. doi:10.1001/jamaneurol.2013.5857.
- Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, Nakashima I, Apostolos-Pereira SL, Talim N, Simm RF, Martins Lino AM, Misu T, Leite MI, Aoki M, Fujihara K: **Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.** *Neurology* 2014. doi:10.1212/WNL.000000000000101.
- Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS, Papadopoulos MC: **Neutrophil protease inhibition reduces NMO-IgG-induced damage in mouse brain.** *Ann Neurol* 2012, **71**(3):323–333. doi:10.1002/ana.22686.
- Saadoun S, Waters P, Macdonald C, Bridges LR, Bell BA, Vincent A, Verkman AS, Papadopoulos MC: **T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement.** *J Neuroimmunol* 2011, **235**(1–2):27–32. doi:10.1016/j.jneuroim.2011.03.007.
- Owens GP, Bennett JL, Lassmann H, O'Connor KC, Ritchie AM, Shearer A, Lam C, Yu X, Birlea M, DuPree C, Williamson RA, Hafler DA, Burgoon MP, Gildea D: **Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid.** *Ann Neurol* 2009, **65**(6):639–649. doi:10.1002/ana.21641.
- Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, Glogowska M, Case D, Antel JP, Owens GP, Gildea D, Nessler S, Stadelmann C, Hemmer B: **Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica.** *Ann Neurol* 2009, **66**(5):617–629. doi: 10.1002/ana.21802.
- Zhou D, Lambert S, Malen PL, Carpenter S, Boland LM, Bennett V: **AnkyrinG is required for clustering of voltage-gated Na channels at axon initial segments and for normal action potential firing.** *J Cell Biol* 1998, **143**(5):1295–1304.
- Bhat MA, Rios JC, Lu Y, Garcia-Fresco GP, Ching W, St Martin M, Li J, Einheber S, Chesler M, Rosenbluth J, Salzer JL, Bellen HJ: **Axon-glia interactions and the domain organization of myelinated axons requires neurexin IV/Caspr/Paranodin.** *Neuron* 2001, **30**(2):369–383.
- Mayer MC, Breithaupt C, Reindl M, Schanda K, Rostasy K, Berger T, Dale RC, Brilot F, Olsson T, Jenne D, Probstel AK, Dornmair K, Wekerle H, Hohlfeld R, Banwell B, Bar-Or A, Meinl E: **Distinction and temporal stability of**

- conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. *J Immunol* 2013, **191**(7):3594–3604. doi:10.4049/jimmunol.1301296.
24. Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH: **Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology.** *Proc Natl Acad Sci U S A* 2005, **102**(39):13992–13997. doi:10.1073/pnas.0504979102.
 25. Marta CB, Taylor CM, Coetzee T, Kim T, Winkler S, Bansal R, Pfeiffer SE: **Antibody cross-linking of myelin oligodendrocyte glycoprotein leads to its rapid repartitioning into detergent-insoluble fractions, and altered protein phosphorylation and cell morphology.** *J Neurosci* 2003, **23**(13):5461–5471.
 26. Lee DH, Linker RA: **The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy?** *Expert Opin Ther Targets* 2012, **16**(5):451–462. doi: 10.1517/14728222.2012.677438.
 27. Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Bruck W, Hartung HP, Stadelmann C, Hemmer B: **Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.** *Proc Natl Acad Sci U S A* 2006, **103**(50):19057–19062. doi:10.1073/pnas.0607242103.
 28. Chernoff GF: **Shiverer: an autosomal recessive mutant mouse with myelin deficiency.** *J Hered* 1981, **72**(2):128.
 29. Reindl M, Di Pauli F, Rostasy K, Berger T: **The spectrum of MOG autoantibody-associated demyelinating diseases.** *Nat Rev Neurol* 2013, **9**(8):455–461. doi: 10.1038/nrneurol.2013.118.
 30. Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM: **Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.** *Lancet Neurol* 2013, **12**(6):554–562. doi:10.1016/S1474-4422(13)70076-0.

doi:10.1186/2051-5960-2-35

Cite this article as: Saadoun et al.: Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. *Acta Neuropathologica Communications* 2014 **2**:35.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

